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Bilirubin Influence on Oxidative Lung Damage and
Surfactant Surface Tension Properties
Carlo Dani, MD,1* Elena Martelli, MD,1 Michele Tronchin, PhD,1 Giuseppe Buonocore, MD,2
Mariangela Longini, PhD,2 Alessandro Di Filippo, MD,3 Massimo Giossi, PhD,4
and Firmino F. Rubaltelli, MD1
Summary. To study the hypothesis that hyperbilirubinemia might reduce in vivo oxidative lung
damage while also diminishing lung surfactant surface tension properties during acute lung injury,
we performed a randomized study in a rabbit model of acute lung injury. Twenty rabbits were
randomized to receive bilirubin or saline intravenously. Acute lung injury was induced by lung
lavages with saline. Lung tissue oxidation was evaluated by measuring total hydroperoxide (TH),
advanced oxidation protein products (AOPP), and protein carbonyls (PC) in bronchial aspirate
(BA) samples. Surface surfactant activity was studied in BA samples using a capillary sur-
factometer. Bilirubin BA concentration increased in bilirubin-treated rabbits, while it remained
undetectable incontrols.Asimilar increase inTH,AOPP,andPCbronchial aspirateconcentrations
was found in both the study and control groups, while surfactant surface activity was lower in the
bilirubin than in the control group. We conclude that during hyperbilirubinemia, bilirubin enters the
lung tissue,where it canbedetected inBAfluid.Bilirubin is not effectiveasanantioxidant agent and
exerts a detrimental effect on lung surfactant surface tension properties. These findingsmay have
relevance to themanagement of premature neonates suffering from respiratory distress syndrome
and hyperbilirubinemia. Pediatr Pulmonol. 2004; 38:179–185.  2004 Wiley-Liss, Inc.
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INTRODUCTION
Hyperbilirubinemia is a frequent complication in
newborn infants which generally occurs in the first days
of life. During this period, bilirubin can distribute to many
tissues.1 However, the bilirubin toxic effect has been in-
vestigated primarily in the central nervous system,2 while
little work has been done to assess the possible effects of
bilirubin on other organs, such as the lungs. In fact, in
hyperbilirubinemic preterm infants with respiratory dis-
tress syndrome (RDS), bilirubin can enter the alveolar
space in fluid leaking from capillaries, where its presence
at necroscopy has been called ‘‘yellow hyaline membrane
disease.’’3,4 The presence of bilirubin in alveolar spaces
might result in associated antioxidant effects or interac-
tions with endogenous surfactant, both of which could be
of clinical importance.
Several reports emphasized that the antioxidant poten-
tial of bilirubin in neonates is greater than urates, a-
tochoferol, or ascorbates.5 In fact, although its role in vivo
has not been definitively clarified in infants,6–10 the
antioxidant effect of bilirubin as a scavenger of reactive
species of oxygen was well-documented in vitro11–14 as
well as in animal studies.15 Moreover, bilirubin was
demonstrated to impair the surface tension of natural lung
surfactant in vitro,16 its effect being independent of pH.17
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Based on the above observations, we hypothesized
that, during hyperbilirubinemia, bilirubin might enter
the alveolar space and exert a protective antioxidant effect
on bronchoalveolar tissues, on the one hand, and a detri-
mental effect on lung surfactant surface tension proper-
ties, on the other. To assess this hypothesis, we performed
a prospective, randomized study in which hyperbiliru-
binemia was induced in a juvenile rabbit model of acute
lung injury, and the bilirubin level was measured in serial
bronchial aspirate (BA) samples. Lung tissue oxidative
damage was investigated measuring total hydroperoxide
(TH), advanced oxidation protein products (AOPP), and
protein carbonyl (PC) concentrations in BA samples.
Surfactant surface activity was studied using the capillary
surfactometer method.
MATERIALS AND METHODS
The experimental protocol was designed in compliance
with the recommendations of the European Economic
Community (86/609/CEE) for the care and use of labo-
ratory animals, and was approved by the Animal Care
Committee of the University of Florence.
Animals and Instrumentation
Twenty-four juvenile New Zealand rabbits of either sex
(age 30–40 days) were anesthetized with ketamine
(25 mg/kg intramuscularly) and xylazine (4 mg/kg intra-
muscularly). Anesthesia was maintained with a contin-
uous infusion of ketamine (10 mg/kg/hr) and xylazine
(4 mg/kg/hr). Muscle relaxation was induced by intrave-
nous administration of pancuronium bromide (0.2 mg/kg)
and maintained with 0.1 mg/kg doses as needed to control
movement.
The anterior neck was dissected, and a tracheostomy
was performed. A cuffed endotracheal tube (3.0–3.5 mm
internal diameter, Sheridan Catheter, Argyle, USA) was
placed in the trachea with the tip proximal to the carina.
The endotracheal tube was connected to a continuous-
flow, time-cycled, pressure-limited ventilator (Bird 750
PSV, Viasys). Humidification and heating of the respira-
tory gases were provided with a standard humidifier.
Initially the animals were ventilated with a continuous
flowof 10 l/min, FiO2 1.0, with a peak inspiratory pressure
(PIP) of 12 cmH2O, a positive end expiratory (PEEP) of
2 cm H2O, and a respiratory rate of 25/min.
A carotid artery catheter was inserted for continuous
blood pressure monitoring and blood sampling. The
catheter was connected to pressure transducers, zero-
referenced to midchest level, and a standard limb lead
electrocardiogram (ECG) was used. A vascular cannula
was inserted into the right internal jugular vein for
continuous infusion of fluids (lactate Ringer’s solution at
the rate of 4 ml/kg/hr) and medications. Rectal tempera-
turewas kept within normal range, using electric warming
pads.
During the entire experiment, polygeline (Emagel1)
and/or dopamine, 10–20 mg/kg/min, were administered
as needed to maintain a mean arterial pressure above
65mmHg.Metabolic acidosis (pH<7.25andBE<8mmol/l)
was correctedwith sodiumbicarbonate or THAMinfusion
(in case of hypercapnia, PaCO2 >45 mmHg). Arterial
blood gases and pH were measured with a blood gas
analyzer (Radiometer ABL 610, Copenaghen, Denmark),
correcting for body temperature.
The pH, pO2, and pCO2 were recorded in each animal
before induction of lung injury (t0), and at 15min (t15), 1 hr
(t60), 2 hr (t120), and 4 hr (t240) after beginning mechanical
ventilation, following induction of lung injury. At the
same time of these data recordings, the oxygenation index
and ventilation efficient index were computed as pre-
viously described18–20: OI¼ [mean airway pressure
inspired oxygen fraction/pO2 (mmHg) 100]; VEI¼
3,800/[respiratory rate (PIP PEEP)þ pCO2 (mmHg)],
where VEI relates alveolar ventilation to respirator input
and 3,800 is a constant for estimating alveolar ventilation
(3,800/pCO2), with the assumption of CO2 production near
normal minimal volumes of 5 ml  kg1 min1 in resting
animals.
Experimental Protocol
Thirty minutes after instituting mechanical ventilation,
the animals were randomized by coin toss to receive a
bilirubin solution or saline only, intravenously. To prepare
the solution at a bilirubin concentration of 3.2 mg/ml,
bilirubin (crystalline bilirubin, Sigma Chemical Co.,
St. Louis, MO) was dissolved in 0.5 M NaOH, 0.055 M
phosphate, and 5% beef albumin at pH 7.4 (10:20:70).21
A bilirubin loading dose of 160 mg/kg was administered
over 15min, followed by amaintenance dose of 64mg/kg/
hr until the end of the study. This dose of bilirubin was
estimated to result in a plasma bilirubin level whichwould
range from 200–300 mmol/l.21 Blood samples were
obtained before bilirubin or saline infusion had begun
(T0), after 1 (T1) and 2 (T2) hr of infusion, and at the end of
the study (T3). Total bilirubin plasma level (Btot) was
measured in blood samples by reflectance spectropho-
tometry (MicrobilimeterTM, Ginevri, Rome, Italy). The
accuracy of Btot measurement in our unit was recently
tested, and the correlation between our laboratory method
ABBREVIATIONS
AOPP Advanced oxidation protein products
BA Bronchial aspirate
Btot Total bilirubin plasma level
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and the HPLC Btot measurement was high (r¼ 0.927;
95% CI¼ 0.906–0.944).22
Bronchial aspirate bilirubin and total protein BA
contentweremeasured at T0, T1, T2, andT3. Bilirubin con-
centration wasmeasured by reflectance spectrophotometry
(see above), while protein detection was performed with
the bicinchoninic acid method.23
Induction of Lung Injury
Immediately after bilirubin and saline infusion had
begun, respiratory failure was induced by repeated lung
lavages with 30 ml/kg of warm saline.24,25 Lung lavages
were repeated at 3-min intervals until pO2 was below
100 mmHg at the following ventilator settings: FiO2, 1.0;
PIP, 20 cmH2O; PEEP, 5 cmH2O; and frequency, 60/min.
To achieve this target, 5–6 lavages were required. Then
theventilator settingwas adjusted tomaintain apO2of 55–
80 mmHg and pCO2 of 45–60 mmHg, to avoid hyperoxia
and decrease baro/volutrauma. Maximum ventilator
settings included a PIP of 26 cm H2O, a PEEP of 5 cm
H2O, and a respiratory rate of 60 breaths/min, with
inspiratory/espiratory (I:E) ratio of 1:2.
Bronchial aspirate samples from animals were taken
using the following technique: 1 ml/kg sterile 0.9% saline
was instilled with a 10-ml syringe via an 8F gauge feeding
catheter placed in the ETT, its length calculated so that its
tip would extend 2 cm beyond the distal end of the ETT.
The saline was instilled and immediately aspirated back
into the syringe. The mean volume of saline returned was
1.2 ml. All samples were clarified by centrifugation, and
the supernatant was immediately frozen to 708C and
kept for subsequent analysis. Bronchial aspirate samples
were taken from each animal before lung injury induction
and at the start of bilirubin and saline infusion (T0), after
1 hr (T2) and 2 hr (T2) of bilirubin or saline infusion, and at
the end (T3) of the study.
Oxidative Stress Assay
In each bronchial aspirate sample, we measured the
TH, AOPP, and PC concentrations. Total hydroperoxide
represents a measure of overall oxidative stress, given that
it is the intermediate oxidative product of lipids, peptides,
and amino acids. Its production was measured with a
d-ROMs Kit (Diacron srl, Italy) by the method described
by Buonocore et al.26 This method makes it possible to
estimate the total amount of hydroperoxide present in a
20-ml sample by using a spectrophotometric procedure.
Hydroperoxidic groups were attacked by the iron decom-
partmentalized from transport protein in 1 ml of acetate
buffer at pH 4.8, to catalyse reactive oxygen metabolite
formation by Fenton’s reaction. The peroxy and alkoxy
radicals produced, whose quantities were directly pro-
portional to peroxides present in the bronchial aspirate,
were trapped chemically by 20 ml of chromogen (N,N-
diethyl.para-phenyl-diamine) in an electron-transfer pro-
cess leading to the formation of the radical cation of this
chromogen. The purple color resulting from this reaction
over time was then monitored in a UV-VIS spectro-
photometer (Perkin Elmer l 16, Norwalk, CT) at 505 nm.
The results were expressed in conventional units (Carr
units: the value of 1 Carr unit is equal to a concentration of
0.08 mg/dl of hydrogen peroxide).
Simultaneous determination of AOPP could provide
information regarding another aspect of protein involve-
ment in free radical reactions, i.e., oxidized proteins that
have lost their oxidant properties. We measured AOPP
by the method of Witko-Sarsat et al.,27 using spectro-
photometry on a microplate reader. The AOPP were
calibrated with chloramine-T solutions that absorb at
340 nm in the presence of potassium iodide. In test wells,
200 ml of bronchial aspirate sample diluted 1:5 in
phosphate-buffered saline (PBS) were distributed on a
96-well microtiter plate, and 20 ml of acetic acid were
added. In standardwells, 10 ml of 1.16Mpotassium iodide
were added to 200 ml of chloramine-T solution (0–
100 mmol/l) followed by 20 ml of acetic acid. The
absorbency of the reaction mixture was immediately read
at 340 nm on the microplate reader against a blank con-
taining 200 ml of PBS, 10 ml of potassium iodide, and 20 ml
of acetic acid. Because the absorbency of chloramine-Tat
340 nm is linear up to 100 mol/l, AOPP concentrations
were expressed as mmol/l chloramine-T equivalents.
Protein carbonyl derives from a variety of oxidative
mechanisms that include fragmentation and amine oxida-
tion, and itsmeasurement, therefore, is a sensitive index of
oxidative injury.28 The quantity of PC in a protein sample
can be determined by derivatizing with dinitropheny-
lhydrazine (DNP) and measuring protein-bound DNP
with an anti-DNP antibody. Protein carbonyl concentra-
tion was determined by enzyme-linked immunosorbent
assay (ELISA), using the Zentech PC Test Kit (Zenith
Technology, Dunedin, New Zealand), by the method of
Buss et al.28 The ELISA method enables PC to be
measured quantitatively with microgram quantities of
protein. The assay is set up so that about 1 mg of derivatized
protein is applied to eachwell of the ELISAplate. Proteins
from any sample are incubated at room temperature with
DNP for 45min and nonspecifically adsorbed to anELISA
plate by incubating overnight at 48C. Proteins are probed
with biotinylated anti-DNP antibody followed by strep-
tavidin-linked horseradish peroxidase. Finally, the chro-
matin reagent containing peroxidase is added, and the
peroxidase catalyses the oxidation of tetra-methyl-benzi-
dyne (TMB). The reaction is stopped by adding acid, and
absorbance is measured for each well at 450 nm.
To establish intra- and interassay accuracy, multiple
measurements were performed the same day and for a
wholemonth. THwaswithin 12%,AOPPwaswithin 10%,
and PC precision was within 9%.
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Surface Activity of Surfactant
Surface activity of surfactant was studied using the
capillary surfactometer, as described by Lema et al.29 This
technique evaluates the ability of surfactant to maintain
the patency of a narrow tube. The instrument uses a glass
capillary to simulate a terminal conducting airway. In a
short section, the capillary is constricted (inner diameter,
0.3 mm) to a width similar to that of a human respiratory
bronchiole. Liquid tends to accumulate in this narrow
section, and when a small amount (0.5 ml) of the liquid to
be evaluated is instilled into the constricted section, it
remains there, but will be extruded when pressure,
continuously recorded, is slowly raised at one end of the
capillary. This will cause the blocking liquid to be pushed
away from the narrow section. If it contains well-
functioning pulmonary surfactant, a film will quickly
form at the air-liquid interface, and by exerting high
surface pressure, it will prevent the liquid from returning
to the narrow section of the capillary. Consequently, a
steady flow of air through the capillary will meet no
resistance, and a pressure of zero is recorded during the
entire 120-sec period of pressure recording that follows
the initial extrusion of the liquid. Thus, the capillary is
open 100% of the recording time. If, on the other hand, the
surfactant is inadequate in quantity or quality, the liquid
will return once or repeatedly. The continuous airflow
will meet resistance, and consequently, pressure will not
remain at zero during the entire period of recording
(120 sec). A minicomputer calculates and prints the
percentage of time that pressure remained at zero and
expresses the surface tension properties of surfactant as
open in %. Each sample was studied five times with a
capillary surfactometer.
Tissue Removal and Pathologic Examination
At the end of the experiment, the animals were killed
with an overdose of pentobarbital. The thorax was
carefully opened to check for signs of pneumothorax
and to harvest tissue. The trachea and lungs were removed
and put in a buffered 10% formalin bath for 24 hr. Two
random pulmonary specimens were obtained from the
upper and lower lobes of both lungs. Routine techniques
were used to prepare the tissues for paraffin embedding.
Five-micrometer-thick sections were stained with hema-
toxylin-eosin, and two pathologists performed the blinded
microscopic examination. Terminal airways distension
was graded 0 when it was similar to that of control lungs,
1 when dilated (between 1–1.5 times with respect to the
control airway caliber), and 2 when very dilated (more
than 1.5 times with respect to the control airway caliber).
In addition, the following histological features were
analyzed: areas of atelectasis, interstitial and/or alveolar
edema, inflammatory infiltration, interlobular septa rup-
tures, and desquamation of bronchiolar epithelium. Each
pathological featurewas evaluated as 1whenpresent and 0
when absent. A pulmonary damage score (negative¼ 0,
slight¼ 0–1, moderate¼ 2–3, and severe¼ 4) was
achieved by adding up the score.
Statistical Analysis
In planning our study, we calculated that a sample size
of at least 10 animals in each group would be required
to detect a difference of 50% in TH bronchial aspirate
concentration in the bilirubin group in comparison to the
control group, with 80% power at a 0.05 alpha level.
Results are expressed as mean SD. The data were
analyzed for statistically significant differences by
ANOVA testwithin groups and byStudent’s t-test between
groups. Simple regression analysis was used to assess the
correlation in bilirubin-treated animals between Btot and
bilirubin level in BA samples.
RESULTS
Four animals died during the saline-lavage phase before
randomization, and they were consequently excluded
from further data analysis. Among the remaining animals,
10 rabbits were randomized to receive bilirubin infusion
and 10 to receive saline infusion. Body weight (1.98
0.10 vs. 2.02 0.18 kg) and the number of saline lavages
(6 1 vs. 6 1 times) did not differ significantly between
groups. The animals received 10 (22) ml/kg polygeline
and 2.9 (1.8) mmol/kg of THAM without significant
differences between the bilirubin-treated (11 17 ml/kg;
2.8 2.1 mmol/kg) and untreated (9 22 ml/kg; 3.2
1.5 mmol/kg) rabbits.
Gas Exchange
Fifteen minutes after induction of lung injury (t15),
we observed a significant decrease of pH and pO2 and an
increase of pCO2. The values of pH, pO2, and pCO2
stabilized at t60 and were substantially unchanged at
t120 and t240. The oxygenation index increased and VEI
decreased at t15. Then, OI and VEI improved at t60 and did
not vary at t120 and at t240. The values of pH, pO2, pCO2,
OI, and VEI did not significantly differ between groups.
Bilirubin and Oxidative Stress Assays
Total bilirubin plasma levels were 3.5 0.3, 288.9
22.5, 255.2 25.1, and 268.2 23.1 mmol/l at T0, T1, T2,
and T3 in the bilirubin-treated animals, while the mean
value in the control group was 3.6 0.4 mmol/l (Table 1).
In bilirubin-infused animals, the bilirubin BA concentra-
tion increased from 0 at T0 to 2.5 0.2 at T1, 2.4 0.4
at T2, and 2.6 0.4 mmol/l at T3, while it remained
undetectable in BA samples of control animals (Table 1).
The total protein content of BA samples was similar in the
two groups and ranged from 3.5 0.5 to 4.1 0.7 mg/dl
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(Table 1). A statistically significant correlation was
observed between Btot and bilirubin level in BA samples
(r¼ 0.933, P< 0.0001; Fig. 1).
During the study, we found a significant increase of
TH, AOPP, and PC bronchial aspirate concentrations at
T3 in both groups, without differences between groups
(Table 2). The mean increase of TH from T0 to T3 was
21.7 6.5% in the bilirubin group and 15.1 3.5% in the
control group. The mean increase of AOPP from T0 to T3
was 53.8 25.0% in the bilirubin group and 40.2 20.1%
in the control group. The mean increase of PC from T0
to T3 was 50.2 20.3% in the bilirubin group and 32.3
16.7% in the control group.
Surface Activity of Surfactant
Surfactant surface activity declined after saline lavage
in both groups, but at the end of the study period it was
lower in the bilirubin group than in the control group
(32.1 2.8 vs. 47.7 4.9 open in %; Fig. 2).
Macro-Microscopic Features
On gross examination, the lungs of both groups were
sufficiently aerated except for some areas of atelectasis,
particularly in the lower lobes. On microscopic examina-
tion, all pulmonary specimens showed scattered areas of
collapsed alveolar walls, and some alveoli contained
macrophages. Moreover, distal airways appeared moder-
ately dilated, and some interlobular septa leakages were
observed. These features were confirmed by the pulmon-
ary damage score, which was 2.4 0.6 and 2.6 0.5 in
the bilirubin and control groups, respectively, reflecting
moderately pathologic lung damage, but without a
significant difference noted between groups (P> 0.05).
DISCUSSION
Our results demonstrate that in the hyperbilirubinemic
juvenile rabbit model of acute lung injury, bilirubin is able
to enter the alveolar space during hyperbilirubinemia,
akin to its entry into lung tissue in preterm infants during
RDS,3,4 and that the bilirubin level in BA samples is
directly correlated with Btot.
Our study did not demonstrate any protective effects of
bilirubin in vivo against oxidative lung injury. In fact,
during mechanical ventilation, the degree of lung tissue
oxidationwas similar in the bilirubin-treated anduntreated
animals, as evidenced by the similar changes of TH,
AOPP, and PC in BA samples.
There has been some inconsistency with regard to the
effects of bilirubin as antioxidant. Our results seem to
disagree with previous studies using in vitro11–14 and
animal models,15 both of which demonstrated the anti-
oxidant properties of bilirubin. However, the in vitro
studies, although very accurate, do not parallel what
TABLE 1— Measurements of Bilirubin Plasma Level (mmol/l), Bilirubin Levels in BA
Samples (mmol/l), and Total Protein in BA Samples (mg/dl) in Bilirubin-Treated and Control
Animals Before (T0), After 1 (T1) and 2 hr (T2) of Bilirubin Infusion, and at End (T3) of Study
Period: meanSD
Bilirubin plasma levels
Bilirubin levels in
BA samples
Total protein levels in
BA samples
Bilirubin Controls Bilirubin Controls Bilirubin Controls
T0 3.5 0.3 3.1 0.4 0 0 3.6 0.6 3.5 0.5
T1 288.9 22.5* 4.2 0.3 2.5 0.2* 0 4.1 0.7 3.9 0.6
T2 255.2 25.1* 3.2 0.6 2.4 0.4* 0 3.9 0.4 3.8 0.5
T3 268.2 23.1* 3.8 0.4 2.6 0.4* 0 3.8 0.5 4.0 0.4
*P< 0.0001 vs. T0 and vs. control group.
Fig. 1. Correlations between Btot (mmol/l) and bilirubin concen-
tration in BA samples (mmol/l) in bilirubin-treated animals.
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actually occurs in vivo. In the study of Dennery et al.
performed on Gunn rats, an antioxidant effect of bilirubin
was found only in the circulatory compartment, where
bilirubin has the highest concentration.15 In fact, and
consistent with our findings, in that same study, jaundiced
animals exposed to hyperoxia exhibited a lung content of
thiobarbituric acid-reactive substances and conjugated
dienes similar to that of nonjaundiced animals, indicating
a similar degree of oxidative lung damage.15 Those and
now our own data indicate that bilirubin, despite its ability
to cause a systemic antioxidant effect, does not appear
able to exert a localized antioxidant effect in lung tissue.
One possible explanation for this phenomenon is that the
concentration of bilirubin in lung tissues (and indeed in
the alveolar space) is too low to let it exert its antioxidant
properties.15 Moreover, our study was performed in a
juvenile rabbit model, and we cannot rule out that the
antioxidant role of bilirubin could be more important in a
premature neonatal model where endogenous levels of
other antioxidants are deficient.
On the other hand, other studies in vitro13 and in vivo30
showed that bilirubin is ineffective in preventing oxidative
damage in some conditions: Mireles et al. demonstrated
in vitro that after oxidative stress, a bilirubin concentra-
tion >30 mg/dl is associated with an increase in protein
oxidation;13 Pauly et al. found that an infusion of 15mg/kg
of bilirubin in infant pigletswas not effective in preventing
the oxidative stress and pulmonary hypertension induced
bygroupB streptococcus.30 Furthermore, previous studies
in preterm infants showed controversial results with regard
to the possible systemic antioxidant properties of bilirubin.
In particular, Yigit et al.,6 Gopinathan et al.,7 and Dani
et al.10 did not find a correlation between serum bilirubin
and plasma antioxidant capacity in preterm infants, while
this correlation was found by Belanger et al.8 and
Hammerman et al.9
In our study, we also investigated the effect of hyper-
bilirubinemia on surfactant surface activity, and we found
that at the endof the studyperiod, activitywas significantly
lower in the bilirubin-treated group than in the control
group. Thus, in our model of lung injury, the increase of
bilirubin plasma level induces the appearance of bilirubin
in bronchoalveolar fluid, which in turn causes a partial
inhibition of surfactant property of lowering surface
tension. This is the first in vivo observation of
the detrimental effect of bilirubin on surfactant surface
activity, although similar findings were described in vitro
by Amato et al.16,17 They demonstrated that bilirubin
impairs the surface tension activity of porcine lipid extract
surfactant but does not affect synthetic surfactant
activity,16 and that this effect occurs independent of pH.17
The different effect of bilirubin on natural and synthetic
surfactant was attributed to the different composition
of the two surfactants: it is possible that tyloxapol, an
alcohol that is contained in the synthetic surfactant,
can ‘‘neutralize’’ the adverse effect of bilirubin, but the
most attractive hypothesis is that bilirubin can interact
with the surfactant proteins SP-B or SP-C, which are
absent in synthetic surfactant.
TABLE 2— Measurements of TH (U Carr/L), AOPP (mmol/l), and PC Levels (nmol/mg of
Proteins) in Bilirubin-Treated and Control Animals Before (T0), After 1 (T1) and 2 hr (T2) of
Bilirubin Infusion, and at End (T3) of Study Period: meanSD
TH AOPP PC
Bilirubin Controls Bilirubin Controls Bilirubin Controls
T0 21.2 1.3 21.2 3.1 1.3 0.4 1.5 0.3 0.8 0.5 0.9 0.2
T1 22.8 1.5 21.0 4.1 1.3 0.8 1.2 0.3 1.1 0.2 1.0 0.3
T2 21.8 3.5 22.4 4.3 1.2 0.4 1.2 0.6 1.2 0.3 1.5 0.4**
T3 25.8 3.8* 24.4 2.9** 2.0 1.4* 2.1 0.3* 1.2 0.3*** 1.2 0.3**
*P< 0.05 vs. T0, T1, and T2.
**P< 0.05 vs. T0 and T1.
***P< 0.05 vs. T0.
Fig. 2. Changes of surfactant surface activity (open in %) in
bilirubin and control groups before lung injury induction (T0), at
1 hr (T1) and 2 hr (T2) after beginning of bilirubin infusion, and at
end (T3) of study period. Data are shown as meanSD. aP<0.05,
T0 vs. T1, T2, and T3.
bP<0.05 T3 vs. T2 and T1 in control group and
T3 in control group vs. T3 in bilirubin group.
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Thus, our in vivo results, which confirm the observa-
tions of Amato et al.,16,17 might have practical implica-
tions for the management of jaundiced infants affected by
respiratory distress syndrome requiring exogenous sur-
factant treatment. It is possible thatmore intense treatment
of hyperbilirubinemia, or a more aggressive treatment
with exogenous surfactant, may be useful in the treatment
of jaundiced infants with respiratory distress syndrome.
In conclusion, we demonstrated that in this animal
model of acute lung injury, hyperbilirubinemia induced
by the intravenous injection of bilirubin results in the
presence of bilirubin in BA fluid. This bilirubin is not
effective as an antioxidant agent and exerts a detrimental
effect on the surface tension properties of lung surfactant.
These results suggest the opportunity of investigating the
possible correlation between hyperbilirubinemia and the
severity of respiratory distress syndrome in jaundiced
newborn infants with respiratory failure.
REFERENCES
1. Bloomer JR, Berk PD, Vergalla J, Berlin NI. Influence of albumin
on the extravascolar distribution of bilirubin. Clin Sci Mol Med
1973;45:517–522.
2. Cashore WJ. The neurotoxicity of bilirubin. Clin Perinatol
1990;17:437–447.
3. Valdoes Dapena MA, Nissim JE, Arey JB, Godleski J, Schaaf HD,
Haust MD. Yellow pulmonary hyaline membrane. J Pediatr 1976;
89:128–132.
4. Morgenstern B, Klionsky B, Doshi N. Yellow hyaline membrane
disease. Identification of the pigment and bilirubin binding.
Lab Invest 1981;44:514–518.
5. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A.
A novel method for measuring antioxidant capacity and its
application to monitoring the antioxidant status in premature
neonates. Clin Sci 1993;84:407–412.
6. Yigit S, Yurdakok M, Kilinc K, Oran O, Erdem G, Tekinalp G.
Serum malondialdehyde concentrations in babies with hyperbi-
lirubinemia. Arch Dis Child Fetal Neonatal Ed 1999;80:235–237.
7. Gopinathan V, Miller NJ, Milner AD, Rice Evans CA. Bilirubin
and ascorbate antioxidant activity in neonatal plasma. FEBS Lett
1994;349:197–200.
8. Bellanger S, Lavole JC, Chessex P. Influence of bilirubin on the
antioxidant capacity of plasma in newborn infants. Biol Neonate
1997;71:233–238.
9. Hammerman C, Goldstein R, Kaplan M, Eran M, Goldschmidt D,
Eidelman AI, Gartner LM. Bilirubin in the premature: toxic waste
or natural defense? Clin Chem 1998;44:2551–2553.
10. Dani C, Martelli E, Bertini G, Pezzati M, Filippi L, Rossetti M,
Rizzati G, Rubaltelli FF. Bilirubin plasma level and oxidative
stress in preterm infants. Arch Dis Child Fetal Neonatal Ed 2003;
88:119–123.
11. Wu TW, Wu J, Li RK, Mickle D, Carey D. Albumin-bound
bilirubin protects human ventricular myocites oxyradical damage.
Biochem Cell Biol 1991;69:683–688.
12. Stocker R, Yamamoto Y, McDonagh AF, Spitz DR, Glazer AN,
Ames BN. Bilirubin is an antioxidant of possible physiological
importance. Science 1987;235:1043–1046.
13. Mireles LC, Lum MA, Dennery PA. Antioxidant and cytotoxic
effects of bilirubin on neonatal erythrocytes. Pediatr Res 1999;45:
355–362.
14. Stocker R, Glazer AN, Ames BN. Antioxidant activity of
albumin-bound bilirubin. Proc Natl Acad Sci USA 1987;84:
5918–5922.
15. Dennery PA, McDonagh AF, Spitz DR, Rogers PA, Stevenson
DK. Hyperbilirubinemia results in reduced oxidative injury in
neonatal Gunn rat exposed to hyperoxia. Free Radic Biol Med
1995;19:395–404.
16. Amato M, Schurch S, Grunder R, Bachofen H, Burri PH.
Influence of bilirubin on surface tension properties of lung
surfactant. Arch Dis Child 1996;75:191–196.
17. Amato M, Schurch S, Grunder R, Bachofen H, Burri PH. Effects
of acidosis on bilirubin-lipid extract surfactant interaction. Biol
Neonate 1995;68:301–307.
18. Al-Rahmani A, Awad K, Miller TF, Wolfson MR, Shaffer TH.
Effects of partial liquid ventilation with perfluorodecalin in the
juvenile rabbit lung after saline injury. Crit Care Med 2000;28:
1459–1464.
19. Boynton BR, Carlo WA, Jobe AH. New therapies for neonatal
respiratory failure. New York: Cambridge University Press; 1994.
p 185.
20. Notterh RH, Egan EA, Kwong MS, Holm BA, Shapiro DI. Lung
surfactant replacement in premature lambs with extracted lipid
from bovine lung lavage: effect of dose, dispersion technique, and
gestational age. Pediatr Res 1985;19:569–577.
21. Roger C, Koziel V, Vert P, Nehlig A. Effects of bilirubin infusion
on local cerebral glucose utilization in the immature rat. Dev
Brain Res 1993;19:115–130.
22. Rubaltelli FF, Glenn RG, Loskamp N, Modi N, Roth-Kleiner M,
Sender A, Vert P. Transcutaneous bilirubin measurement: a
multicenter evaluation of a new device. Pediatrics 2001;107:
1264–1271.
23. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH,
Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC.
Measurement of protein using bicinchonininc acid. Anal Biochem
1985;150:76–85.
24. Lachman B, Robertson B, Vogel J. In vivo lung lavage as an ex-
perimental model of the respiratory distress syndrome. Acta
Anaesthesiol Scand 1980;24:231–236.
25. Rotta AT, Gunnarsson B, Fuhrman BP, Hernan LJ, Steinhorn DM.
Comparison of lung protective ventilation strategy in a rabbit
model of acute injury. Crit Care Med 2001;29:2176–2184.
26. Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R. Total
hydroperoxide and advanced oxidation protein products in
preterm hypoxic babies. Pediatr Res 2000;47:221–224.
27. Witko-Sarsat V, Frielander M, Capeillere-Blandin C, Nguyen-Khoa
T, Thu Nguyen A, Zingraff J, Jungers P, Drueke T, Descamps-
Latsca B. Advanced oxidation protein products as a novel
marker of oxidative stress in uremia. Kidney Int 1998;49:1304–
1313.
28. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC.
Protein carbonyl measurement by a sensitive ELISAmethod. Free
Radic Biol Med 1997;23:361–366.
29. Lema G, Dryja D, Vargas I, Enhorning G. Pseudomonas
aeruginosa from patients with cystic fibrosis affects function of
pulmonary surfactant. Pediatr Res 2000;47:121–126.
30. Pauly TH, Smith M, Gillespie M. Bilirubin as an antioxidant:
effect of non group B streptococci-induced pulmonary hyperten-
sion in infant piglets. Biol Neonate 1991;60:320–326.
Bilirubin Influence on Oxidative Lung Damage 185
